Volatile Organic Compounds for the Assessment of Liver Disease

Launched by IMPERIAL COLLEGE LONDON · Nov 6, 2020

Keywords

ClinConnect Summary

This clinical trial is studying whether a simple breath test can help detect liver diseases like fibrosis, cirrhosis, or liver cancer (hepatocellular carcinoma) at an early stage. Researchers believe that certain compounds in our breath, known as volatile organic compounds, may indicate the presence of these liver conditions. If you are a patient visiting a liver clinic and have suspected or confirmed liver or pancreatic disease, you may be approached to provide a breath sample for this important research.

To participate, you should be between the ages of 18 and 90 and able to understand the study details so you can give informed consent. Unfortunately, if you cannot provide consent, are outside the age range, or cannot fast before the test, you won’t be eligible. If you join the study, you can expect to provide a breath sample, which will be analyzed to look for specific markers that could indicate your liver health. This trial is currently recruiting participants, and your involvement could contribute to better methods for diagnosing liver diseases in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients seen in secondary care with suspected or confirmed liver / pancreatic disease or hepatocellular carcinoma / pancreatic cancer
• • Patients able to understand and retain the information provided, thereby being able to give informed consent for inclusion in this study
• Exclusion Criteria:
• • Patients who lack capacity or unable to provide informed consent.
• • Any patient outside the established age range (18-90years).
• • Patients unable to fast.